RxDoctor Payments Data

Bridgett Hynes, APRN

Internal Medicine · Palatka, FLNPI 1447984299

Payments from drug & device makers

$1,154in general payments, 2019–2025

Across 62 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$344
  • Novo Nordisk$182
  • Bayer$158
  • Lilly USA, LLC$157
  • GSK$73
  • Corcept Therapeutics$69
  • plus $170 from 5 others

What the payments were for

  • Food & beverage$1,154100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,154 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$337,126
Medicare patients
318
Services billed
6,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin89$116,342
OzempicSemaglutide82$114,867
MounjaroTirzepatide58$112,081
TrulicityDulaglutide38$80,790
FarxigaDapagliflozin Propanediol37$50,355
EliquisApixaban37$46,085
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$44,233
MyrbetriqMirabegron41$33,748
XareltoRivaroxaban22$27,327
RybelsusSemaglutide11$19,825
Tresiba Flextouch U-200Insulin Degludec15$18,817
JanuviaSitagliptin Phosphate15$15,966
Tresiba Flextouch U-100Insulin Degludec18$14,006
SymbicortBudesonide/Formoterol Fumarate34$13,990
LinzessLinaclotide17$13,620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$157$192,87096 claims
Novo NordiskOzempic, Rybelsus$182$134,69293 claims
AstraZenecaFarxiga, Symbicort$344$64,34571 claims
GSKTrelegy Ellipta, Breo Ellipta$73$55,90458 claims
PfizerEliquis, Toviaz$22$49,79050 claims
AbbVieLinzess, Synthroid$51$19,07964 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Palatka

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →